This abstract (full text available to journal subscribers) builds on previous work, including a 2013 article, accessible in full at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706567/
Edens C1, Collins ML2, Goodson JL3, Rota PA4, Prausnitz MR5.
Vaccine. 2015 Mar 12. pii: S0264-410X(15)00285-6. doi: 10.1016/j.vaccine.2015.02.074. [Epub ahead of print]
Very high vaccination coverage is required to eliminate measles, but achieving high coverage can be constrained by the logistical challenges associated with subcutaneous injection. To simplify the logistics of vaccine delivery, a patch containing micron-scale polymeric needles was formulated to encapsulate the standard dose of measles vaccine (1000 TCID50) and the immunogenicity of the microneedle patch was compared with subcutaneous injection in rhesus macaques. The microneedle patch was administered without reconstitution with diluent, dissolved in skin within 10min, and caused only mild, transient skin erythema. Both groups of rhesus macaques generated neutralizing antibody responses to measles that were consistent with protection and the neutralizing antibody titers were equivalent. In addition, the microneedle patches maintained an acceptable level of potency after storage at elevated temperature suggesting improved thermostability compared to standard lyophilized vaccine. In conclusion, a measles microneedle patch vaccine was immunogenic in non-human primates, and this approach offers a promising delivery method that could help increase vaccination coverage.
Copyright © 2015 Elsevier Ltd. All rights reserved.